FLT3 and acute myeloid leukemia: By contrast, in the recent randomized phase III LACEWING trial of older/unfit adults with newly diagnosed FLT3-mutated AML, there was no difference in OS for gilteritinib plus azacitidine vs azacitidine alone (9.8 vs 8.9 months), although these results were clouded by the fact that many patients on the azacitidine arm terminated the study early and received subsequent FLT3 inhibitor therapy [62].